Evaluation of Single Doses of GSK962040 in Critically Ill Patients With Enteral Feed Intolerance
Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The aims of MOT112571 are to assess the pharmacodynamic effects, safety, tolerability,
pharmacokinetics, and potential therapeutic benefit of single doses of GSK962040 in
critically ill patients with delayed gastric emptying and who are intolerant to enteral
feeding.